Access to experimental drugs for terminally ill patients

JAMA

Volumn 300, Issue 23, 2008, Pages 2793-2795

  Falit, Benjamin P ^a   Gross, Cary P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; NOTE; PATIENT CARE; PATIENT RIGHT; PRIORITY JOURNAL; TERMINALLY ILL PATIENT; UNITED STATES;

EID: 58049215226     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.828     Document Type: Note

References (7)

1. St George D. Time in a bottle: a new generation of precision cancer drugs is seducing patients with the possibility of adding months, even years, to their lives: if only they could get their hands on them. Washington Post. January 18, 2004: W10.
2. Abigail Alliance v Von Eschenbach, 495 F3d 695 (DC Cir 2007).
3. Expanded access to investigational drugs for treatment use. Fed Regist. 2006;71(240):75147-75168.
4. Jacobson PD, Parmet WE. A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach. JAMA. 2007;297(2):205-208.
5. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol. 2007;25(2):209-216.
6. En banc Brief for Appellants at 54, Abigail Alliance v Von Eschenbach, 495 F3d 695 (DC Cir 2007).
7. Krohmal BJ, Emanuel E. Access and ability to pay: the ethics of a tiered health care system. Arch Intern Med. 2007;167(5):433-437.